Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E CDKN2A loss NRAS Q61K||melanoma||predicted - resistant||Cobimetinib + Vemurafenib||Case Reports/Case Series||Actionable||In a clinical case study, a melanoma patient harboring BRAF V600E and NRAS Q61K experienced progressive disease after a response to combination therapy with Zelboraf (vemurafenib) and Cotellic (cobimetinib), land was found to have acquired loss of CDKN2A (PMID: 34376578).||34376578|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|